![]() “Given the favorable safety profile and continued public interest in ivermectin, the ACTIV-6 team will continue to study this higher dose to determine whether it will make enough of a difference to be considered for the treatment of mild-to-moderate COVID-19,” said Susanna Naggie, the Duke University principal investigator overseeing the study’s clinical coordinating center.The Food and Drug Administration (FDA) echoed the CDC’s warning against the use of ivermectin for prevention or treatment of COVID-19. Many people who elected to take the drug to treat their symptoms took the product meant for livestock, a move that landed many in the hospital.ĬLICK HERE TO READ MORE FROM THE WASHINGTON EXAMINER But it is not authorized or approved as a treatment for COVID-19. It is also approved for use in animals to prevent heartworm. The Food and Drug Administration has approved the drug to be used to treat parasitic illness and in some instances can be applied topically. The authors of the new study said that further studies into the use of the drug will need to be investigated in order to determine whether it has any significant benefit. Most studies of ivermectin’s role in treating COVID-19 have been small and less rigorous, producing inconsistent results. “We found no important effects of treatment with ivermectin on the secondary outcomes” such as recovery, the need for a ventilator, and the time to death. “We did not find a significantly or clinically meaningful lower risk of medical admission to a hospital or prolonged emergency department observation (primary composite outcome) with ivermectin administered for 3 days at a dose of 400 μg per kilogram per day than with placebo,” researchers behind the Brazil study wrote. This difference did not meet the threshold for showing the superiority of ivermectin over a placebo. A large clinical study published in the New England Journal of Medicine in March found that, among 1,300 people with COVID-19 in Brazil who received either ivermectin or a placebo, only 11 more patients who got the placebo were hospitalized than those who took ivermectin. ![]() The usage of ivermectin to treat COVID-19 in people soared during the pandemic primarily driven by anecdotal evidence that had little scientific evidence to back it up. “Given these results, there does not appear to be a role for ivermectin outside of a clinical trial setting, especially considering other available options with proven reduction in hospitalizations and death,” Hernandez said. The study, which included more than 1,500 people, concluded that ivermectin should only be used for treating COVID-19 in trial settings. The authors reported that hospitalization was higher among people who took ivermectin compared to those who received a placebo. “Overall, most people improved their symptoms whether they took ivermectin or not.” “There was no significant benefit in our primary endpoint of resolution of symptoms in mild-to-moderate COVID-19 illness,” said Adrian Hernandez, the study’s administrative principal investigator. Pierre Kory, also gained major attention for touting the drug to the Senate Homeland Security Committee in 2020.įDA EXPERTS RECOMMEND COVID-19 VACCINES FOR CHILDREN UNDER 6 A prominent doctor whose arguments in favor of ivermectin have also gained federal attention, pulmonary care specialist Dr. The drug received considerable traction, including interest from popular podcaster Joe Rogan, who took a cocktail of drugs including ivermectin to treat his coronavirus infection. Researchers at Duke University and Vanderbilt University concluded in a pre-print study that the drug ivermectin, approved for treating parasitic illnesses in livestock, did very little to resolve symptoms and nothing to prevent hospitalizations and deaths. Ivermectin, an anti-parasitic drug that gained popularity as a COVID-19 treatment, provided no significant benefit in alleviating symptoms or preventing hospitalizations and deaths, a new study found.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |